Global Anesthetic Drugs Expected to Hit $6.4 Billion by 2026 –

DUBLIN–(BUSINESS WIRE)–The “Global Anesthetic Drugs Market (2021-2026) by Drug Type, Route of Administration, Application, Geography, Competitive Analysis and Impact of Covid-19 with Ansoff Analysis” report has been added to from offer.

The Global Anesthetic Drugs Market is estimated to be valued at USD 4.68 Billion in 2021 and is projected to reach USD 6.42 Billion by 2026, growing at a CAGR of 6.52%.

The major growth drivers of the global anesthetic drugs market are the growing number of operations such as cardiac, orthopedic, general surgeries and pain management.

Also, technological advancements in drug delivery devices, development of specific targeted drugs and patient monitoring devices to monitor physiological parameters of patients during and after anesthesia and reduction of side effects of anesthetic drugs are all expected to drive the growth of the market over the forecast period. Moreover, the falling cost of newly created drugs and decreasing recovery period after surgery are creating more opportunities for the market.

However, some side effects caused by anesthetic drugs, including nausea, vomiting, disorientation, sore throat, muscle pain, etc., and the strict policies and regulations imposed by the government hinder and create challenges for market growth.

The global anesthetic drugs market is segmented on the basis of drug type, route of administration, application and geography.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Why buy this report?

  • The report offers a comprehensive assessment of the global Anesthetic Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.

  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.

  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.

Market dynamics


  • Increase in surgical procedures

  • Substantial demand for postoperative pain relief options

  • The rise of pain management


  • Side effects of some anesthetic drugs


  • Innovations in drug delivery technologies

  • Growth of health sectors in developing countries


  • Lack of qualified anesthesiologists

Companies cited

  • Abbott Laboratories

  • AbbVie Inc

  • Aspen Pharmacare Holdings Limited

  • Astra Zeneca plc

  • B. Braun Melsungen AG

  • Baxter International Inc.

  • Claris Lifesciences Limited

  • Dr. Reddy’s Laboratories

  • Eisai Co.Ltd

  • F. Hoffmann-La Roche SA

  • Fresenius SE & Co. KGaA

  • Glenmark Pharmaceuticals Limited

  • Hikma Pharmaceuticals PLC

  • Hospira, Inc.

  • Maruishi Pharmaceutical Co.,Ltd

  • Nuventra Pharma Sciences

  • Pacira Pharmaceuticals, Inc.

  • Paion UK Ltd

  • Pfizer Inc.

  • Piramal Enterprises LTD

  • Septodont Healthcare India Pvt. ltd

  • Slayback Pharma LLC

  • Teva Pharmaceutical Industries Limited

  • Troikaa Pharmaceuticals Ltd.

  • Viatris inc.

For more information about this report visit

Comments are closed.